Patents by Inventor Qiyong Peter Liu

Qiyong Peter Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240167022
    Abstract: Described herein are compositions and methods for treating cancer comprising single-stranded 5? uncapped triphosphate or biphosphate modified RNA oligonucleotides complementary to a miRNA which is highly expressed in a tumor microenvironment in comparison to a non-tumor environment.
    Type: Application
    Filed: December 29, 2021
    Publication date: May 23, 2024
    Inventors: Robert Michael Dudley, Qiyong Peter Liu, Subrata Kumar Ghosh
  • Patent number: 11975274
    Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: May 7, 2024
    Assignee: Velico Medical, Inc.
    Inventors: Qiyong Peter Liu, Herman E. Snyder, Kyle D. Erickson, Evan P. Ordway, William J. Merritt, Richard Meehan, Robert R. Andrews, Clair Strohl, Jihae Sohn, Mark A. Popovsky, Lisa A. Buckley
  • Publication number: 20240131063
    Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the mean size of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 25, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Jihae Sohn, Lisa A. Buckley, Mark A. Popovsky, Qiyong Peter Liu, Herman E. Snyder, Evan P. Ordway, William J. Merritt, Robert R. Andrews, Clair Strohl
  • Publication number: 20240131062
    Abstract: The spray dried plasma by the nature of its characteristics and the process by which it is made allows for a dried plasma with reduced pathogens. It has at least three aspects of pathogen reduction that results in a plasma product with reduced or no pathogens. The first aspect relates to a spray drying disposable and machine that eliminates or minimizes the introduction of pathogens into the spray drying process and is referred to as the anti-contamination process. The second aspect of pathogen reduction relates to the spray drying process and parameters that reduces pathogens that may be present in the donor plasma, and/or inhibit pathogen growth and/or pathogen proliferation introduced by the donor plasma. The third aspect results in reduced pathogens occurring during storage of the dried plasma wherein the manufacturing and storage conditions are such that pathogens are reduced, and/or pathogen growth and/or pathogen proliferation are inhibited.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 25, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Mark A. Popovsky, Lisa A. Buckley, Jihae Sohn, Evan P. Ordway, Qiyong Peter Liu, Robert R. Andrews, Herman E. Snyder, William J. Merritt, Clair Strohl, Russell J Barron
  • Publication number: 20240123368
    Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).
    Type: Application
    Filed: January 17, 2023
    Publication date: April 18, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Robert R. Andrews, Herman E. Snyder, William J. Merritt, Evan P. Ordway, Clair Strohl, Qiyong Peter Liu, Jihae Sohn
  • Publication number: 20240109000
    Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).
    Type: Application
    Filed: September 15, 2022
    Publication date: April 4, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Qiyong Peter Liu, Herman E. Snyder, Kyle D. Erickson, Evan P. Ordway, William J. Merritt, Richard Meehan, Robert R. Andrews, Clair Strohl, Jihae Sohn
  • Publication number: 20240091667
    Abstract: A method of treating plasma with a pretreatment solution that has a physiologically compatible spray dry stable acidic substance (SDSAS) and an amino acid, prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.
    Type: Application
    Filed: September 14, 2023
    Publication date: March 21, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Lisa A. Buckley, Mark A. Popovsky, Jihae Sohn, Qiyong Peter Liu, William J. Merritt
  • Publication number: 20240091155
    Abstract: A method of treating plasma with a pretreatment solution that has a physiologically compatible spray dry stable acidic substance (SDSAS) and an amino acid, prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.
    Type: Application
    Filed: September 15, 2022
    Publication date: March 21, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Qiyong Peter Liu, William J. Merritt, Jihae Sohn
  • Publication number: 20240091666
    Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).
    Type: Application
    Filed: January 17, 2023
    Publication date: March 21, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Richard Meehan, Robert R. Andrews, Herman E. Snyder, William J. Merritt, Evan P. Ordway, Clair Strohl, Qiyong Peter Liu, Jihae Sohn
  • Publication number: 20240042070
    Abstract: Described herein are compositions and methods for treating cancer using a RIG-I agonist precursor comprising single-stranded 5? uncapped triphosphate or biphosphate antisense oligonucleotide having a sequence complementary to an endogenous miRNA; optionally wherein the compositions and methods comprise a nanoparticle for targeted delivery of the RIG-I agonist precursor and a radiolabel to a tumor micro environment.
    Type: Application
    Filed: June 28, 2023
    Publication date: February 8, 2024
    Inventors: Robert Michael Dudley, Qiyong Peter Liu, Dustan Bonnin, Subrata Kumar Ghosh
  • Patent number: 11806431
    Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: November 7, 2023
    Assignee: Velico Medical, Inc.
    Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya, Abdul W. Khan
  • Publication number: 20220040110
    Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Applicant: Velico Medical Inc.
    Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya
  • Publication number: 20210290545
    Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Applicant: Velico Medical Inc.
    Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya
  • Patent number: 11052045
    Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: July 6, 2021
    Assignee: Velico Medical, Inc.
    Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya
  • Publication number: 20190246629
    Abstract: The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment.
    Type: Application
    Filed: April 22, 2019
    Publication date: August 15, 2019
    Applicants: Velico Medical, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
  • Publication number: 20190200602
    Abstract: The present invention relates to a platelet additive solution (PAS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.
    Type: Application
    Filed: March 5, 2019
    Publication date: July 4, 2019
    Applicants: Velico Medical, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Qiyong Peter Liu, Karin Hoffmeister, M, Robert Sackstein
  • Publication number: 20190203175
    Abstract: The present invention relates to a platelet protection solution (PPS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof.
    Type: Application
    Filed: September 10, 2018
    Publication date: July 4, 2019
    Applicant: Velico Medical, Inc.
    Inventor: Qiyong Peter Liu
  • Patent number: 10271541
    Abstract: The present invention relates to a platelet additive solution (PAS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 30, 2019
    Assignees: Velico Medical, Inc, The Brigham and Women's Hospital, Inc.
    Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
  • Publication number: 20180000066
    Abstract: The present invention relates to a platelet protection solution (PPS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
  • Publication number: 20170370952
    Abstract: The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, the reconstituted plasma mediates platelet adhesion and aggregation about the same as or greater than the starting plasma prior to spray drying. The present invention also relates to an assay for determining platelet adhesion and aggregation using microfluidic flow cell system having a shear flow. The assay assesses labeled whole blood samples having reconstituted plasma having spray dried plasma and a reconstitution solution; platelets; and red blood cells. After inducing a shear flow under conditions suitable for clot formation, coverage area of the platelets, intensity of the platelets, morphology, or a combination thereof is detected to determine platelet accumulation (e.g., platelet adhesion and aggregation).
    Type: Application
    Filed: April 7, 2017
    Publication date: December 28, 2017
    Inventors: Qiyong Peter Liu, Ryan Christopher Carney, Andrew Peter Cap, Michael Adam Meledeo